Understanding why muscles weaken in myotonic dystrophy type 1
Official title: Mechanisms of Skeletal Muscle Pathogenesis in Myotonic Dystrophy Type 1
Funded at Baylor College of Medicine · NIH-11387396 · Data updated 2026-11-12
This project aims to find what causes progressive muscle weakness in people with myotonic dystrophy type 1 by studying how abnormal RNA affects muscle cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | September 6, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $132,536 |
| NIH project number | 3R01AR082852-03S1 |
| Project ID | NIH-11387396 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with genetically confirmed myotonic dystrophy type 1, especially those willing to provide blood or muscle tissue samples, are the most relevant candidates for participation or sample donation.
✕Less likely to help
People without DM1 or those seeking immediate clinical treatment should not expect direct personal benefit from this basic-mechanism research.
What this research studies
They study how expanded CTG repeats in the DMPK gene produce toxic RNA that forms nuclear clumps and traps key splicing proteins. In mouse muscle models they examine how loss of MBNL proteins and increased CELF1 lead to wrong RNA splicing and muscle damage. The team will compare these laboratory findings with human blood and tissue samples to connect molecular changes to patient muscle symptoms. The goal is to reveal mechanisms that could point to future treatment targets.
Why it matters
Potential benefit: If successful, this work could identify molecular targets to prevent or reverse muscle wasting in people with DM1.
How similar studies have gone: Previous research established that CUG-repeat RNA sequesters MBNL proteins and causes mis-splicing, but the reasons for CELF1 upregulation in muscle remain less understood.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Cooper, Thomas a — Baylor College of Medicine
- Study coordinator: Cooper, Thomas a
Related research
Other NIH-funded projects on the same topics.
-
New small molecule therapeutics to help myotonic dystrophy
A new NIH-funded project tests specially designed small molecules to lower harmful RNA activity in myotonic dystrophy and related diseases, aiming to reduce disease-driving RNA effects.
-
Mechanisms of muscle disease in myotonic dystrophy type 1
This project looks at why skeletal muscles weaken and waste away in adults with myotonic dystrophy type 1 and aims to uncover the underlying molecular causes.
-
Extracellular vesicle biomarkers to monitor DM1 using urine and blood samples
A study looking for easy, noninvasive biomarkers in urine and blood to track disease activity in people with myotonic dystrophy type 1.
-
Calcium Channel Blocker in DM1: Can amlodipine help myotonic dystrophy type 1
This study tests whether the calcium‑channel blocker amlodipine can improve symptoms and survival in myotonic dystrophy type 1 (DM1).
-
Preparing therapies for DM1 across ages, with a focus on children
A broad, patient-focused effort to bring promising DM1 therapies to both children and adults by enriching trial readiness, biomarkers, and natural history data.
-
Biological factors that drive variability in myotonic dystrophy
This grant explores why myotonic dystrophy can look very different from person to person by studying its genetic changes and how they affect muscle in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.